Phillip M. Pierorazio, MD
Urology
Headshot of Phillip M. Pierorazio, MD

Phillip M. Pierorazio, MD

Urology
Accepting new patients
Sees patients age 18 and up
Penn Urology University City
View 2 additional locations
Headshot of Phillip M. Pierorazio, MD
Penn Medicine Provider

About me

  • Chief, Section of Urology, Penn Presbyterian Medical Center
  • Professor of Surgery at the Hospital of the University of Pennsylvania

I am a board-certified urologist with training and expertise in urologic cancers.  I have expertise in all malignancies of the urinary tract, but my clinical and academic practice focuses on kidney cancer (renal cell carcinoma), testicular cancer (germ cell tumors), upper tract urothelial cancer, and prostate cancer.  I offer patients both open and minimally invasive surgeries including laparoscopic and robotic surgeries of the kidney, bladder, prostate, and retroperitoneal lymph node dissection for testicular cancer.  I am a firm believer that surgery is a last option and prefer non-operative management whenever possible – but routinely perform surgeries for complex cancers and patients. 

My research team includes basic science researchers, statisticians, and other urologists both inside and outside Penn Medicine.  We focus on cancer biomarkers, improving outcomes for complex surgeries, evaluating the quality of care through a cancer journey, and minimizing the impact of surgical treatments.  I run the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry - one of the largest active surveillance registries for patients with small kidney tumors. I am involved in a number of national guideline panels, including both the American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) Guidelines Committees, for Kidney, Testicular and Upper Tract Urothelial Cancer. 

While I experience tremendous satisfaction from generating research and guidelines that influence the care of cancer patients around the world, in my opinion, there is no greater impact in medicine than taking a patient through a cancer journey.  My greatest joy comes from the relationships we build through diagnosis, treatment, and the survivorship journey.

My education and training

  • Columbia UniversityMedical School
  • Johns Hopkins HospitalResidency
Watch video featuring Phillip M. Pierorazio, MD on YouTube

Spoken languages

English
English

Reviews

Average Rating

761 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Knowledgeable, courteous, patient
Anonymous
October 2026
He is extremely thorough and knowledgeable.
Anonymous
October 2026
Good appt. Like the provider.
Anonymous
October 2026
Satisfied with care.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Pierorazio is a Penn Medicine provider. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

All conditions and treatments

Research

Publications

Wang C, Pierorazio PM, Alsyouf M. Cure is Expected, Choice is the Challenge: Patient-Reported Outcomes and the Path Forward for Stage II Testis Cancer Treatment , J Urol: 2026


Sanchez VA, Dinh PC Jr, Monahan PO, Fung C, Althouse S, Stump T, Rooker J, Dolan ME, Feldman DR, Hamilton RJ, Pierorazio PM, Martin NE, Huddart R, Kollmannsberger C, Root J, Sesso HD, Weinzierl M, Einhorn LH, Frisina RD, Travis LB. Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study , EClinicalMedicine, 94: 2026,103841


Rowe SP, Murtazaliev S, Amindarolzarbi A, Sheikhbahaei S, Meyer AR, Javadi MS, Wood M, Kaufmann B, Goel R, Viglianti BL, Pavlovich CP, Singla N, Pierorazio PM, Baras AS, Epstein JI, Baraban E, Allaf ME, Solnes LB, Oldan JD, Patel HD, Gorin MA. Performance of (99m)Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience , J Urol: 2026


Soliman C, Sathianathen N, Corcoran NM, Wuethrich PY, Furrer MA; CAMUS Study Group Collaborators. International Multicentre Analysis of Perioperative Complications Following Major Urologic Oncologic Surgery: Early Results from More than 130 000 Procedures from the CAMUS Collaborative , Eur Urol Focus: 2026


Briggs LG, Psutka SP, Van Ligten MJ, Beck KL, Sinha D, Gill VS, Alkhatib KY, Durant AM, Bain PA, Quillen J, Dodoo C, Pierorazio PM, Abdul-Muhsin H, Tyson MD, Trinh QD, Parke SC. Exercise, diet and psychological support for patients with testicular cancer , Nat Rev Urol: 2026


Rowe SP, Murtazaliev S, Amindarolzarbi A, Sheikhbahaei S, Meyer AR, Javadi MS, Wood M, Kaufmann B, Goel R, Viglianti BL, Pavlovich CP, Singla N, Pierorazio PM, Baras AS, Epstein JI, Baraban E, Allaf ME, Solnes LB, Oldan JD, Patel HD, Gorin MA. Reply by Authors , J Urol: 2026


Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO; International Neoadjuvant Kidney Cancer Consortium. Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium. , Lancet Oncol. 2025 Oct;26(10):e536-e546. doi: 10.1016/S1470-2045(25)00345-6. PMID: 41038202 Review.: 2025


Briggs LG, Psutka SP, Van Ligten MJ, Beck KL, Sinha D, Gill VS, Alkhatib KY, Durant AM, Bain PA, Quillen J, Dodoo C, Pierorazio PM, Abdul-Muhsin H, Tyson MD, Trinh QD, Parke SC. Exercise, diet and psychological support for patients with testicular cancer. , Nat Rev Urol. 2025 Sep 22. doi: 10.1038/s41585-025-01089-5. Online ahead of print. PMID: 40983774 Review.: 2025


Alkhatib KY, Cheaib JG, Pallauf M, Alam R, Patel HD, Wlajnitz T, Singla N, Chang P, Wagner AA, Pavlovich CP, McKiernan JM, Guzzo TJ, Allaf ME, Pierorazio PM. Active Surveillance versus Primary Intervention for Clinical T1a Kidney Tumors: Twelve-Year Experience of the DISSRM Prospective Comparative Study. , J Urol. 2025 Apr 22:101097JU0000000000004583. doi: 10.1097/JU.0000000000004583. Online ahead of print.PMID: 40262276: 2025


Lattanzio K, Alkhatib K, Guzzo T, Lee DJ, Pierorazio P, Bivalacqua T, Schurhamer B. . Case study: Pulsed electric field ablation for salvage prostate cancer ablation , Urol Case Rep. 2025 Mar 25;60:103023. doi: 10.1016/j.eucr.2025.103023. eCollection 2025 May.PMID: 40270519 Free PMC article.: 2025


View all publications